sorafenib has been researched along with zoledronic acid in 9 studies
| Studies (sorafenib) | Trials (sorafenib) | Recent Studies (post-2010) (sorafenib) | Studies (zoledronic acid) | Trials (zoledronic acid) | Recent Studies (post-2010) (zoledronic acid) |
|---|---|---|---|---|---|
| 6,520 | 730 | 5,251 | 4,108 | 620 | 2,610 |
| Protein | Taxonomy | sorafenib (IC50) | zoledronic acid (IC50) |
|---|---|---|---|
| Carbonic anhydrase 12 | Homo sapiens (human) | 0.316 | |
| Geranylgeranyl pyrophosphate synthase | Homo sapiens (human) | 0.318 | |
| Carbonic anhydrase 2 | Homo sapiens (human) | 0.062 | |
| 72 kDa type IV collagenase | Homo sapiens (human) | 7 | |
| Farnesyl pyrophosphate synthase | Homo sapiens (human) | 0.2144 | |
| Farnesyl diphosphate synthase | Escherichia coli K-12 | 1.1 | |
| Farnesyl pyrophosphate synthase | Leishmania donovani | 0.11 | |
| Geranylgeranyl pyrophosphate synthase | Saccharomyces cerevisiae S288C | 0.424 | |
| Carbonic anhydrase 9 | Homo sapiens (human) | 5.323 | |
| Carbonic anhydrase 14 | Homo sapiens (human) | 0.092 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (11.11) | 29.6817 |
| 2010's | 8 (88.89) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Afshari, CA; Eschenberg, M; Hamadeh, HK; Lee, PH; Lightfoot-Dunn, R; Morgan, RE; Qualls, CW; Ramachandran, B; Trauner, M; van Staden, CJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Hasegawa, Y; Matsubara, A; Mita, K; Ohdan, H | 1 |
| Kong, LQ; Sun, HC; Tang, ZY; Wang, L; Wu, WZ; Xiong, YQ; Xu, HX; Zhang, W; Zhu, XD; Zhuang, PY | 1 |
| Omrčen, T; Rini, B; Schmidinger, M; Sella, A; Szczylik, C; Torday, L; Vrdoljak, E | 1 |
| Agerbaek, M; Donskov, F; Fode, K; Folkmar, TB; Smidt-Hansen, T | 1 |
| Chai, ZT; Gao, DM; Kong, LQ; Lu, L; Sun, HC; Tang, ZY; Wang, L; Wang, WQ; Wu, WZ; Xu, HX; Zhang, JB; Zhang, W; Zhu, XD; Zhuang, PY | 1 |
| Natori, T; Yamaguchi, M | 1 |
| Choueiri, TK; Heng, DY; Lin, X; McKay, RR; Perkins, JJ; Simantov, R | 1 |
2 review(s) available for sorafenib and zoledronic acid
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Bisphosphonates and vascular endothelial growth factor-targeted drugs in the treatment of patients with renal cell carcinoma metastatic to bone.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carcinoma, Renal Cell; Diphosphonates; Humans; Imidazoles; Indazoles; Indoles; Kidney Neoplasms; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Pyrroles; Sorafenib; Sulfonamides; Sunitinib; Vascular Endothelial Growth Factor A; Zoledronic Acid | 2013 |
7 other study(ies) available for sorafenib and zoledronic acid
| Article | Year |
|---|---|
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Assay; Biological Transport; Cell Line; Cell Membrane; Chemical and Drug Induced Liver Injury; Cytoplasmic Vesicles; Drug Evaluation, Preclinical; Humans; Liver; Rats; Reproducibility of Results; Spodoptera; Transfection; Xenobiotics | 2010 |
Multidisciplinary treatment including sorafenib stabilized the bone metastases of renal cell carcinoma in an immunosuppressed renal transplant recipient.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Bone Density Conservation Agents; Bone Neoplasms; Carcinoma, Renal Cell; Diphosphonates; Humans; Imidazoles; Immunosuppressive Agents; Incidental Findings; Interferon-alpha; Kidney Neoplasms; Kidney Transplantation; Male; Middle Aged; Nephrectomy; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Radiotherapy, Adjuvant; Sorafenib; Tomography, X-Ray Computed; Treatment Outcome; Zoledronic Acid | 2009 |
Depletion of tumor-associated macrophages enhances the effect of sorafenib in metastatic liver cancer models by antimetastatic and antiangiogenic effects.
Topics: Angiogenesis Inhibitors; Animals; Benzenesulfonates; Carcinoma, Hepatocellular; Cell Line, Tumor; Clodronic Acid; Diphosphonates; Drug Therapy, Combination; Humans; Imidazoles; Liposomes; Liver Neoplasms, Experimental; Lung Neoplasms; Macrophages; Male; Mice; Mice, Nude; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Xenograft Model Antitumor Assays; Zoledronic Acid | 2010 |
Combination of zoledronic Acid and targeted therapy is active but may induce osteonecrosis of the jaw in patients with metastatic renal cell carcinoma.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Agents; Bone Neoplasms; Carcinoma, Renal Cell; Cohort Studies; Diphosphonates; Everolimus; Female; Follow-Up Studies; Fractures, Spontaneous; Humans; Imidazoles; Indazoles; Indoles; Interleukin-2; Kidney Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Pyrimidines; Pyrroles; Radiography, Panoramic; Retrospective Studies; Sirolimus; Sorafenib; Spinal Cord Compression; Sulfonamides; Sunitinib; Survival Rate; Zoledronic Acid | 2013 |
Antiangiogenic therapy promoted metastasis of hepatocellular carcinoma by suppressing host-derived interleukin-12b in mouse models.
Topics: Angiogenesis Inhibitors; Animals; Carcinoma, Hepatocellular; Cell Line, Tumor; Dendritic Cells; Diphosphonates; Heterografts; Humans; Imidazoles; Immunosuppression Therapy; Indoles; Interleukin-12 Subunit p40; Killer Cells, Natural; Liver Neoplasms; Lung Neoplasms; Macrophages; Male; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Mice, Knockout; Mice, Nude; Neoplasm Transplantation; Neoplastic Cells, Circulating; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Sunitinib; Zoledronic Acid | 2013 |
[Complete response after sorafenib therapy plus zoledronic acid for advanced hepatocellular carcinoma with bone metastasis - a case report].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carcinoma, Hepatocellular; Diphosphonates; Humans; Imidazoles; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Remission Induction; Sorafenib; Zoledronic Acid | 2013 |
Prognostic significance of bone metastases and bisphosphonate therapy in patients with renal cell carcinoma.
Topics: Aged; Antineoplastic Agents; Axitinib; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Agents; Bone Neoplasms; Carcinoma, Renal Cell; Diphosphonates; Disease-Free Survival; Female; Humans; Hypocalcemia; Imidazoles; Indazoles; Indoles; Interferon-alpha; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Pamidronate; Phenylurea Compounds; Prognosis; Pyrroles; Renal Insufficiency; Retrospective Studies; Sirolimus; Sorafenib; Sunitinib; Survival Rate; TOR Serine-Threonine Kinases; Vascular Endothelial Growth Factor A; Zoledronic Acid | 2014 |